✦ LIBER ✦

Diamond-Blackfan Anemia in Japan: Clinical Outcomes of Prednisolone Therapy and Hematopoietic Stem Cell Transplantation

✍ Scribed by Shouichi Ohga; Hideo Mugishima; Akira Ohara; Seiji Kojima; Kohji Fujisawa; Keiko Yagi; Masamune Higashigawa; Ichiro Tsukimoto; for the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology

Publisher: Carden Jennings Publishing
Year: 2004
Tongue: English
Weight: 189 KB
Volume: 79
Category: Article
ISSN: 0925-5710
DOI: 10.1007/bf02983529

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Polymorphisms of the methylenetetrahydro

Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation

✍ Inho Kim; Kyung-Hun Lee; Jin Hee Kim; Eun Kyung Ra; Sung-Soo Yoon; Yun-Chul Hong 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 154 KB

In-hospital complications of autologous

In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies : Clinical and economic outcomes from the nationwide inpatient sample

✍ Jeffrey A. Jones; Muzaffar H. Qazilbash; Ya-Chen T. Shih; Scott B. Cantor; Cathe 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

## Abstract ## BACKGROUND. Autologous hematopoietic stem cell transplantation (auto HSCT) is standard of care therapy for multiple myeloma and Hodgkin and non‐Hodgkin lymphomas in front‐line and salvage settings, respectively. Complications remain common, but population‐based estimates of their fr

Clinically-based determination of safe D

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients

✍ Daniele Lilleri; Fausto Baldanti; Marta Gatti; Francesca Rovida; Luca Dossena; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract Transplantation Centers using human cytomegalovirus (HCMV) antigenemia‐based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view